Not Yet RecruitingNot Applicable

Inturlekin L33 in Ankylosing Spondylities Patients and Its Relation to Subclinical Atherosclerosis

45 participantsStarted 2024-09

Plain-language summary

detect level of Inturlekin 33 in ankylosing spondyilits patient measure CIMT (carotid intima media thickness ) by carotid duplex to detect subclinical atherosclerosis in ankylosing spondyitis patients detect the relation between IL33 and subclinical atherosclerosis in Ankylosinig Spondylitis patients

Who can participate

Age range

20 Years – 40 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * patient diagnosed as Ankylosing Spondylitis * Age (20-40) Exclusion Criteria: * Patients with other rheumatic diseases/other SPA types * Participants with history of CVD event in past or present * Patient experiencing cardiovascular revascularization surgery or cerebrovascular disorder within past 6 months. * Patient with other risk factor for atherosclerosis.

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

detect level of IL33 in AS patients

Timeframe: 3 years

Trial details

NCT IDNCT06564155

SponsorAssiut University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-08

Contact for this trial

Aya AbuAli, master

01097833248 ayaa.m.abuali471@gmail.com

View on ClinicalTrials.gov More Ankylosing Spondylitis trials